Evidence map›Paper›PMID 37020589›Full record

Trial reportFrontiers in endocrinology2023

Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical trial.

Sahar Rostami, Ashraf Alyasin, Mojtaba Saedi, Saeid Nekoonam, Mahshad Khodarahmian, Ashraf Moeini, Fardin Amidi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 5 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Effects ofFrontiers in nutrition · 2026
    Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sahar RostamiDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Ashraf AlyasinDepartment of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mojtaba SaediDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Saeid NekoonamDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mahshad KhodarahmianDepartment of Infertility, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ashraf MoeiniDepartment of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Fardin AmidiDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRRoyan Institute · IRShariati Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: In a randomized, triple-blind, placebo-controlled clinical trial (RCT) including 50 infertile women with endometriosis candidate for assisted reproductive techniques (ART), we studied the effect of Astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and early pregnancy outcomes. Methods: Before and after 12 weeks of AST treatment (6 mg per day), blood serum and follicular fluid (FF) samples were collected from 50 infertile women with endometriosis stage III/IV undergoing ART. Pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and OS markers (malondialdehyde [MDA], superoxide dismutase [SOD], catalase [CAT], and total antioxidant capacity [TAC]) were measured in the serum and FF. ART outcomes were also compared between the groups. Results: Increased serum levels of TAC (398.661 ± 57.686 Conclusion: AST pretreatment can modulate inflammation and OS in endometriosis-induced infertile patients. ART outcomes also improved after 12 weeks of AST therapy. Our results suggest that AST can be a potential therapeutic target for infertile patients with endometriosis undergoing ART.

Indexed as

EndometriosisFibrinolytic AgentsAntioxidantsCase-Control StudiesFemaleFollicular FluidHumansInfertility, FemaleInflammationInterleukin-6Oxidative StressPregnancyPregnancy OutcomeSuperoxide DismutaseTumor Necrosis Factor-alphaXanthophyllsAntioxidantsastaxanthineFibrinolytic AgentsInterleukin-6Superoxide DismutaseTumor Necrosis Factor-alphaXanthophyllsantioxidantsassisted reproductive techniques (ARTs)astaxanthin (AST)endometriosisfemale infertility

Identifiers

PMID37020589
PMCPMC10067663
OpenAlexW4327981884

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.